Ken Jones has been appointed president and chief executive officer of Astellas Pharma Europe Ltd. (APEL), the European subsidiary Astellas Pharma, Inc. Mr. Jones previously served as chief operating officer of APEL, since July 2007. He succeeds Masao Yoshida, who has been appointed president and chief executive officer of Astellas Pharma US, Inc., the U.S. subsidiary of Astellas Pharma Inc.

Mr. Jones, commented: “I am delighted and honored to be taking on this new role and I look forward to building on Astellas Pharma Europe’s considerable achievements. In spite of the tough market conditions, we’re in a strong position and have clear strategies for growth through expanding and developing our core franchises. Having the stability of a large company combined with the agility of a smaller operation gives us a real competitive advantage in terms of our ability to achieve these goals by responding rapidly to opportunities in the market. I hope to continue to drive solid growth for Astellas Pharma Europe in the years ahead.”

Mr. Jones joined the company (then Yamanouchi) in January 2003 as vice president, European Marketing. In 2005, when Fujisawa and Yamanouchi merged to produce Astellas, he was promoted to senior vice president of sales, marketing and medical. Previously, Mr. Jones spent 16 years with Allergan, Inc., holding senior international marketing positions across the U.S., Europe and Japan.
@font-face { font-family: “Cambria”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; }